Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8246654 | 0.85 | SLC6A3 (0.33) | PIK3CDSMN1; SMN2KDM4EGRIN2DGRIN3B | |
| SCHEMBL21107430 | 0.84 | PIK3CD (0.43) | PIK3CDHRH3SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL102034 | 0.82 | SMN1; SMN2 (0.41) | HRH3SMN1; SMN2ACHE | |
| SCHEMBL1687229 | 0.82 | PIK3CD (0.42) | PIK3CDHRH3SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL803898 | 0.81 | PIK3CD (0.45) | PIK3CDHRH3ACHESIGMAR1 | |
| SCHEMBL10092708 | 0.80 | ACHE (0.50) | ACHESIGMAR1 | |
| SCHEMBL12309037 | 0.80 | NCF1 (0.37) | KDM4EACHE | |
| SCHEMBL13683795 | 0.80 | PIK3CD (0.44) | PIK3CDHRH3SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL599158 | 0.80 | NCF1 (0.52) | PIK3CDHRH3SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL24508569 | 0.79 | PIK3CD (0.38) | PIK3CDHRH3GRIN2DGRIN3BADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-8906909-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8461157-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| US-8367663-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8338448-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CD 37/4885HRH3 1994/4885SMN1; SMN2 4184/4885 |
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | HDAC6, HDAC9, HDAC7 | PIK3CD 10/4885HRH3 1544/4885SMN1; SMN2 2725/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | PIK3CD 1678/4885HRH3 3548/4885SMN1; SMN2 716/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | PIK3CD 846/4885HRH3 2319/4885SMN1; SMN2 2731/4885 |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CD 39/4885HRH3 1964/4885SMN1; SMN2 4192/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | PIK3CD 3395/4885HRH3 4267/4885SMN1; SMN2 3607/4885 |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CD 37/4885HRH3 1994/4885SMN1; SMN2 4184/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885HRH3 3631/4885SMN1; SMN2 2647/4885 |
| US-20130172330-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | PIK3CD 2264/4885HRH3 1231/4885SMN1; SMN2 4379/4885 |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | PIK3CD 577/4885HRH3 3236/4885SMN1; SMN2 2524/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885HRH3 3631/4885SMN1; SMN2 2647/4885 |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | KRAS, HRAS, KSR2 | PIK3CD 194/4885HRH3 1184/4885SMN1; SMN2 4049/4885 |
| US-20100029634-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | PIK3CD 2264/4885HRH3 1231/4885SMN1; SMN2 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.